GLP1R and Insulin resistance: From day 56 after birth, GLP-1 agonist exenatide was administered twice daily to a DCM (TG9) mouse model. TG9 mice predictably develop congestive HF and secondary insulin resistance, with mortality occurring at 12 weeks of age.